IRF4 ligand-1 is an IRF4 ligand that can be used for the synthesis of PROTACs, such as dIRF4-2 [1].
In Vitro, IRF4 ligand-1 is an IRF4 ligand that can be used for the synthesis of PROTACs, such as dIRF4-2. dIRF4-2 is a selective IRF4 PROTAC degrader with a DC50 value of 2.2 μM. dIRF4-2 exhibits anticancer activity against myeloma[1].
References:
[1]. Agius MP, et al. Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma. Nat Chem Biol. 2026 May 28.
In Vitro, IRF4 ligand-1 is an IRF4 ligand that can be used for the synthesis of PROTACs, such as dIRF4-2. dIRF4-2 is a selective IRF4 PROTAC degrader with a DC50 value of 2.2 μM. dIRF4-2 exhibits anticancer activity against myeloma[1].
References:
[1]. Agius MP, et al. Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma. Nat Chem Biol. 2026 May 28.